<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169832</url>
  </required_header>
  <id_info>
    <org_study_id>49653/416</org_study_id>
    <secondary_id>ISRCTN54136716</secondary_id>
    <nct_id>NCT00169832</nct_id>
  </id_info>
  <brief_title>Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery: The VICTORY Trial</brief_title>
  <acronym>VICTORY</acronym>
  <official_title>A Multicenter Randomized Double-Blind Trial Comparing Rosiglitazone to Placebo for the Prevention of Atherosclerosis Progression After Coronary Bypass Surgery in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HYPOTHESES&#xD;
&#xD;
        -  Rosiglitazone in diabetic patients with previous coronary bypass surgery may prevent or&#xD;
           slow the progression of atherosclerosis in SVGs and native coronary arteries.&#xD;
&#xD;
        -  Rosiglitazone has favorable effects on adipose tissue distribution variables as well as&#xD;
           on thrombosis, pro-inflammatory, and lipid profiles in diabetic patients after coronary&#xD;
           bypass artery surgery.&#xD;
&#xD;
        -  Rosiglitazone therapy influences favorably metabolism and clinical outcomes in diabetic&#xD;
           patients after coronary artery bypass surgery.&#xD;
&#xD;
      OBJECTIVES&#xD;
&#xD;
        -  PRIMARY To assess the efficacy of rosiglitazone to reduce atherosclerosis progression in&#xD;
           vein grafts in diabetic patients after coronary bypass surgery by using IVUS imaging&#xD;
           after a 12 mo follow-up.&#xD;
&#xD;
        -  SECONDARY&#xD;
&#xD;
             -  To prospectively compare the secondary IVUS endpoints.&#xD;
&#xD;
             -  To prospectively compare the angiographic endpoints.&#xD;
&#xD;
             -  To prospectively compare the metabolic risk factor endpoints.&#xD;
&#xD;
             -  To prospectively compare the body composition and distribution endpoints.&#xD;
&#xD;
             -  To prospectively compare the clinical outcomes of rosiglitazone versus standard&#xD;
                care using composite endpoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN&#xD;
&#xD;
      This is a prospective multicenter randomized placebo-controlled double-blind trial assessing&#xD;
      the efficacy and safety of rosiglitazone in the prevention of atherosclerosis progression in&#xD;
      vein grafts and native coronary arteries of diabetic patients. Stable diabetic patients with&#xD;
      previous coronary bypass surgery (≥ 1 year ≤ 10 years) will be screened. After baseline&#xD;
      evaluation, all eligible patients will undergo baseline coronary angiogram. IVUS will be&#xD;
      performed in a segment length of at least 40 mm in a SVG suitable for IVUS analysis and in a&#xD;
      segment length of at least 20 mm in the anastomosed native coronary artery corresponding to&#xD;
      the SVG chosen. Following the IVUS procedure, patients will be randomized to either&#xD;
      rosiglitazone treatment or to placebo in addition to their standard clinical care. Study drug&#xD;
      will be titrated over an 8-week period up to a dose of 8 mg/day (or to maximum tolerated&#xD;
      dose). The patients will receive the study drug or the placebo for 50-54 weeks in a&#xD;
      double-blind manner. At the beginning and at 2, 4, 6, 8, 10 and 12 months of treatment,&#xD;
      patients will be subjected to a set of morphological, physiological and metabolic&#xD;
      evaluations. At the final visit (12 months), patients will also be submitted to IVUS and&#xD;
      angiography.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plaque volume in one SVG (by IVUS)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 Change in plaque volume in segment of anastomosed coronary artery</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Changes in lumen and total vessel volumes and lumen plaque total vessel areas in SVG and coronary segments</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 Changes in qualitative plaque characterization in the SVG and coronary segments</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4 Patients showing atherosclerosis changes</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 Atherosclerosis changes concordance and discordance</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 New occlusions in native coronary arteries or SVGs</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7 Changes in reference and minimum lumen diameters of the SVG</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8 Per patient percentage of initially patent SVGs that had significant progression of atherosclerosis at the site of greatest change at follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9 Changes of indices for comprehensive lipid thrombosis and pro-inflammatory profiles as well as glucose-insulin homeostasis, microalbuminuria, adhesion molecules, adipokines, and other markers relevant to the evaluation and management of cardiovascular</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10 Changes in abdominal areas and volumes of adipose tissue areas</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>11 Changes in body composition, body weight, waist circumference and BMI</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 Clinical laboratory parameters, physical examinations, vital signs, ECGs, concomitant medication and adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>13 Death, MI, TIA, stroke, hospitalization and ischemia-driven interventions</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>14 Fluid retention</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">193</enrollment>
  <condition>Diabetes</condition>
  <condition>Coronary Artery Bypass Grafting</condition>
  <arm_group>
    <arm_group_label>Rosiglitazone (Avandia)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone or placebo</intervention_name>
    <description>Rosiglitazone 4 to 8 mg/day or placebo, for 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Rosiglitazone (Avandia)</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        AT SCREENING:&#xD;
&#xD;
          1. Male or female, aged ≥ 40 years &amp; ≤ 75 years.&#xD;
&#xD;
          2. Women of childbearing potential with contraceptive measure, or of non-childbearing&#xD;
             potential or surgically sterile.&#xD;
&#xD;
          3. Type 2 diabetes mellitus.&#xD;
&#xD;
          4. Patients with no new medication for hyperglycemia and no change in dose of oral&#xD;
             hypoglycemic medication within the last 3 mo prior to screening.&#xD;
&#xD;
          5. Diabetic patients with ischemic heart disease and CABG with at least one SVG (≥1 yr &amp;&#xD;
             ≤10 yrs).&#xD;
&#xD;
          6. Patient agrees to participate.&#xD;
&#xD;
          7. Patient legally capable of giving consent and understand what participation in study&#xD;
             entails, potential risks and benefits, freedom to withdraw without any prejudice to&#xD;
             subsequent medical arrangement or treatment, sign an ICF prior to any protocol&#xD;
             specific procedure.&#xD;
&#xD;
        AT IVUS &amp; ANGIOGRAPHY (VISIT 2):&#xD;
&#xD;
        Subject eligible if at least 1), 2) and 3) of the following criteria apply:&#xD;
&#xD;
          1. Patient with at least 1 patent SVG.&#xD;
&#xD;
          2. Segment length of at least 40 mm in SVG suitable for IVUS.&#xD;
&#xD;
          3. Reference of target (SVG) diameter ≥ 2.5 mm.&#xD;
&#xD;
             If anastomosed native coronary artery or non grafted coronary artery can be evaluated,&#xD;
             the following criteria must be met:&#xD;
&#xD;
          4. Reference of target anastomosed native coronary artery or non grafted coronary artery&#xD;
             diameter≥ 2.5 mm.&#xD;
&#xD;
          5. Segment length of at least 20 mm in anastomosed native coronary artery corresponding&#xD;
             to SVG chosen or, in case of impossibility of performing IVUS in the anastomosed&#xD;
             coronary artery, a non grafted coronary artery (≥ 30 mm length segment) might be used&#xD;
             for reference.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        AT SCREENING:&#xD;
&#xD;
          1. Clinically significant abnormality at screening tests &amp; exams.&#xD;
&#xD;
          2. Type 1 diabetes or history of diabetic ketoacidosis.&#xD;
&#xD;
          3. Uncontrolled type 2 diabetes mellitus.&#xD;
&#xD;
          4. Recent MI or ACS (≤ 90 days).&#xD;
&#xD;
          5. History of hypersensitivity to thiazolidinediones (TZD) or compounds of similar&#xD;
             chemical structures.&#xD;
&#xD;
          6. Last LVEF≤ 35%.&#xD;
&#xD;
          7. SBP&gt;170mmHg or DBP&gt;100mmHg at screening/baseline should be appropriately treated and&#xD;
             under control prior to randomization.&#xD;
&#xD;
          8. Unstable or Canadian Cardiovascular Society class III and IV angina, acute heart&#xD;
             failure or congestive heart failure (NYHA class III and IV).&#xD;
&#xD;
          9. History of hepatocellular reaction/severe oedema/other potentially fluid-related AE&#xD;
             associated with use of any TZD or PPAR-γ agonist.&#xD;
&#xD;
         10. Hepatic disease.&#xD;
&#xD;
         11. Renal dysfunction.&#xD;
&#xD;
         12. Anemia.&#xD;
&#xD;
         13. TG ≥ 10 mmol/L.&#xD;
&#xD;
         14. History of PCI in all SVG(s).&#xD;
&#xD;
         15. Known occlusion(s) of all SVG(s).&#xD;
&#xD;
         16. Treatment involving TZD within 3 mo prior to screening.&#xD;
&#xD;
         17. Chronic use (≥ 6 mo) of insulin for glycemic control at any time in the past or&#xD;
             administration of insulin any time within the last 12 mo.&#xD;
&#xD;
         18. Allergy to contrast agents.&#xD;
&#xD;
         19. Current intake of anorectic agents or have been taken off an anorectic agent or&#xD;
             equivalent within 3 mo prior to screening.&#xD;
&#xD;
         20. Patients for whom oral or injectable corticosteroids are used on a regular or&#xD;
             recurrent basis.&#xD;
&#xD;
         21. Recent history/suspicion of current drug abuse or alcohol abuse within last 6 mo.&#xD;
&#xD;
         22. Women breast feeding, pregnant, or planning to become pregnant during conduct of trial&#xD;
             and for 30 days after study completion.&#xD;
&#xD;
         23. Other illness that precludes survival.&#xD;
&#xD;
         24. History of malignancy within the last 5 yrs.&#xD;
&#xD;
         25. Concurrent participation in other investigational device or drug studies and/or having&#xD;
             received any experimental therapeutic agents within 30 days of the screening.&#xD;
&#xD;
         26. Use of any investigational drug for glycemic control within 3 mo of the screening.&#xD;
&#xD;
         27. Patient travelling out of town/country for periods exceeding 2 mo.&#xD;
&#xD;
         28. Medical condition which may interfere with intake and/or absorption of study&#xD;
             medication.&#xD;
&#xD;
         29. Patients unwilling or unable to comply with procedures.&#xD;
&#xD;
         30. Recent major surgery within 90 days of the screening.&#xD;
&#xD;
        AT IVUS AND ANGIOGRAPHY (VISIT 2):&#xD;
&#xD;
          1. PCI was performed on the target segment(s) after CABG.&#xD;
&#xD;
          2. Target SVG and/or target native coronary artery show ≥ 50% angiographic lesion&#xD;
             precluding IVUS.&#xD;
&#xD;
          3. Thrombus/thrombus aspect in target vessels.&#xD;
&#xD;
          4. Target vessel has been subjected to surgical endarterectomy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier F Bertrand, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval Hospital Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Pierre Despres, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval Hospital Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Poirier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval Hospital Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QEII Health Sciences Center - Halifax Infirmary</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences - Mc Master Clinic</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRMSBC</name>
      <address>
        <city>Bonaventure</city>
        <state>Quebec</state>
        <zip>G0C 1E0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Notre-Dame Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laval Hospital</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitarion Son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>October 9, 2008</last_update_submitted>
  <last_update_submitted_qc>October 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Olivier F Bertrand, MD PhD</name_title>
    <organization>Hopital Laval</organization>
  </responsible_party>
  <keyword>Atherosclerosis progression</keyword>
  <keyword>Ischemic heart disease</keyword>
  <keyword>Saphenous vein graft</keyword>
  <keyword>Metabolic risk factors</keyword>
  <keyword>Rosiglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

